hVIVO inks deal to manufacture human hMPV virus for challenge trial

(Alliance News) - hVIVO PLC on Wednesday said it has signed a deal to manufacture a human ...

Alliance News 28 June, 2023 | 1:16PM
Email Form Facebook Twitter LinkedIn RSS

(Alliance News) - hVIVO PLC on Wednesday said it has signed a deal to manufacture a human metapneumovirus virus and to conduct a characterisation study with an unnamed North American firm.

The London-based specialist contract research organisation providing testing for infectious and respiratory vaccines said it intends to conduct a subsequent hMPV challenge trial in 2024 to test the efficacy of its vaccine candidate.

The compliant virus manufacturing activities will start immediately, and are expected to be completed in the first half of 2024.

hVIVO will then carry out a characterisation study to identify a safe and infectious dose of wild-type hMPV in up to 36 healthy adult volunteers. Depending on the outcome of the study, the company will begin conducting hMPV challenge trials from the second half of 2024.

Chief Executive Officer Yamin Khan said: "We are delighted to be developing the industry's first commercial hMPV human challenge model. The continued expansion of our challenge model portfolio aligns with our mission to deliver today's healthcare by empowering tomorrow's innovation. We hope to help our client to bring their treatment to patients faster through the utilisation of a new unique human challenge model".

Shares in hVIVO were down 1.4% at 14.55 pence each in London on Wednesday afternoon.

By Sabrina Penty, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

Email Form Facebook Twitter LinkedIn RSS

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
hVIVO PLC 27.50 GBX 0.92 -

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

© Copyright 2024 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures